Claro Advisors LLC Has $239,000 Stake in Biogen Inc. $BIIB

Claro Advisors LLC lowered its holdings in Biogen Inc. (NASDAQ:BIIB) by 33.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,902 shares of the biotechnology company’s stock after selling 975 shares during the period. Claro Advisors LLC’s holdings in Biogen were worth $239,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. NewSquare Capital LLC grew its position in Biogen by 134.6% during the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock worth $31,000 after buying an additional 140 shares in the last quarter. State of Michigan Retirement System raised its holdings in Biogen by 633.7% in the 2nd quarter. State of Michigan Retirement System now owns 291,303 shares of the biotechnology company’s stock valued at $36,585,000 after acquiring an additional 251,600 shares in the last quarter. TIAA Trust National Association lifted its position in shares of Biogen by 2.3% during the 2nd quarter. TIAA Trust National Association now owns 4,443 shares of the biotechnology company’s stock valued at $558,000 after acquiring an additional 100 shares during the period. Plato Investment Management Ltd grew its holdings in shares of Biogen by 361.6% during the 2nd quarter. Plato Investment Management Ltd now owns 4,939 shares of the biotechnology company’s stock worth $618,000 after purchasing an additional 3,869 shares in the last quarter. Finally, Hills Bank & Trust Co grew its holdings in shares of Biogen by 17.4% during the 2nd quarter. Hills Bank & Trust Co now owns 5,586 shares of the biotechnology company’s stock worth $702,000 after purchasing an additional 829 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen Stock Performance

Shares of Biogen stock opened at $156.74 on Friday. The company’s 50 day moving average price is $145.59 and its two-hundred day moving average price is $134.51. The firm has a market capitalization of $22.99 billion, a P/E ratio of 14.98, a P/E/G ratio of 1.17 and a beta of 0.10. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.50 and a quick ratio of 1.79. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $176.95.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, beating analysts’ consensus estimates of $3.89 by $0.92. The company had revenue of $2.53 billion during the quarter, compared to analysts’ expectations of $2.34 billion. Biogen had a return on equity of 13.85% and a net margin of 15.31%.Biogen’s revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the company earned $4.08 EPS. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. On average, equities analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 517 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total transaction of $69,045.35. Following the sale, the insider directly owned 5,772 shares in the company, valued at approximately $770,850.60. The trade was a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Citigroup reaffirmed a “neutral” rating on shares of Biogen in a research report on Wednesday, September 24th. Robert W. Baird cut their price target on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Royal Bank Of Canada reduced their price target on shares of Biogen from $217.00 to $210.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Mizuho boosted their price objective on shares of Biogen from $169.00 to $177.00 and gave the company an “outperform” rating in a research report on Monday. Finally, BMO Capital Markets raised their target price on Biogen from $128.00 to $150.00 in a report on Friday, October 31st. Ten investment analysts have rated the stock with a Buy rating and eighteen have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $177.46.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.